Clinical studies about the organ protection effect in heart and the kidney of telmisartan

Clinical studies about the organ protection effect in heart and the kidney of telmisartan - Clinical studies about the organ protection effect in heart and the kidney of telmisartan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009796

Enrollment

Registered

2013-01-18

Start date

2012-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ongoing dialysis patients with hypertention.

Interventions

Sart with once-daily dosing of 20mg telmisartan,and increase up to 40-80mg,if there is no problem with the tolerability.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Men or women, age between 20 and 90 years 2)Maintenance dialysis patients 3)Systolic or diastolic pressure >=140/90mmHg 4)Willing and able to provide informed consent

Exclusion criteria

Exclusion criteria: 1))Systolic or diastolic pressure <140/90mmHg 2)Patients with hypersensitivity to this drug 3)Prengnancy and possible pregnancy 4)ALT levels >=500IU/L 5)Patients inadequate for the study

Design outcomes

Primary

Measure	Time frame
Effects on cardiac function and vasucular lesions(Echocardiography,Vascular Ultrasound).	—

Secondary

Measure	Time frame
1)ABI,PWV,SPP 2)Blood parameters CBC:WBC,RBC,PLT Biochemistry: CRP,FBS,HbA1c,AST,ALT,ALP,BUN,UA,s-Cr Others: Blood inflammation factor	—

Countries

Japan

Contacts

Public ContactJunichi Suzuki

University of Tokyo,Graduate School of Medicine Department of Advanced Clinical Medicine Course

03-5800-9116

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026